Beyond Benlysta: New Lupus Treatments in 2026 Including Anifrolumab and CAR-T Therapy

The Lupus Treatment Landscape Is Changing

For decades, lupus treatment relied on a limited toolkit: hydroxychloroquine, corticosteroids, and broad immunosuppressants. The approval of belimumab (Benlysta) in 2011 was the first new lupus-specific drug in over 50 years. Since then, the pace has accelerated dramatically.

Here is where things stand in 2026 — from established therapies to genuinely exciting research that could change how lupus is treated.

Established Biologics

Belimumab (Benlysta)

What it does: Blocks BLyS (B-lymphocyte stimulator), a protein that helps B cells survive. In lupus, overactive B cells produce the autoantibodies that drive the disease.

Status in 2026: Fully established. Available as IV infusion or subcutaneous self-injection. Now approved for both general SLE and lupus nephritis (kidney involvement), based on the BLISS-LN trial.

Who it helps: Patients with active disease despite standard therapy. Particularly effective for reducing flare frequency, lowering steroid dependence, and slowing kidney disease progression.

What patients should know:

• Takes 3-6 months to see the full effect — do not expect immediate results
• Generally well tolerated; most common side effects are nausea and infections
• May be combined with mycophenolate for lupus nephritis

Anifrolumab (Saphnelo)

What it does: Blocks the type I interferon receptor. This is significant because roughly 75% of lupus patients have an overactive interferon signature — essentially, their interferon system is stuck in overdrive, fueling inflammation.

Status in 2026: Approved for moderate-to-severe SLE. Growing real-world data continues to support its efficacy, particularly for skin and joint manifestations.

Who it helps: Patients with active lupus despite standard treatment, especially those with prominent skin disease, joint involvement, and high interferon gene signatures.

What patients should know:

• Administered as an IV infusion every 4 weeks
• The TULIP trials showed significant improvement in disease activity and steroid reduction
• Risk of herpes zoster (shingles) is slightly increased — vaccination beforehand is recommended
• Does not yet have a specific lupus nephritis indication, though research is ongoing

Voclosporin (Lupkynis)

What it does: A calcineurin inhibitor specifically developed for lupus nephritis. It suppresses the overactive immune cells that are damaging the kidneys.

Status in 2026: Approved for lupus nephritis in combination with mycophenolate.

Who it helps: Patients with active lupus nephritis (Class III, IV, or V).

What patients should know:

• Taken orally twice daily
• The AURORA trial showed significantly higher rates of complete kidney response
• Requires blood pressure and kidney function monitoring
• A major advantage over older calcineurin inhibitors is that it does not require drug level monitoring

Emerging Therapies

CAR-T Cell Therapy

This is the most talked-about development in lupus research, and for good reason.

What it does: T cells are extracted from the patient's blood, genetically engineered to target and destroy CD19-positive B cells (the cells producing harmful autoantibodies), and then infused back. It is essentially a deep reset of the immune system's B cell compartment.

Where the research stands:

• Initial case series from Germany (Dr. Georg Schett's group in Erlangen) showed remarkable results — patients achieving drug-free remission after a single treatment
• Multiple clinical trials are now underway across the US, Europe, and Asia
• Early data shows some patients maintaining remission without any immunosuppressive medications for over two years
• Several patients with refractory lupus nephritis showed complete kidney response

Important caveats:

• This is still experimental and not widely available
• The procedure involves chemotherapy conditioning (to make room for the modified cells), which carries real risks
• Long-term safety data is still being gathered
• Cost and accessibility remain major barriers
• Not every patient responds, and some have relapsed

The lupus community is cautiously optimistic. CAR-T therapy represents a fundamentally different approach — instead of managing the disease, it aims to reset the immune dysfunction at its source.

Other Pipeline Treatments

Several other approaches are in various stages of clinical trials:

• Obinutuzumab — an anti-CD20 antibody (similar to rituximab) being studied for lupus nephritis with improved B cell depletion
• Deucravacitinib — a TYK2 inhibitor (oral medication) that showed promise in Phase II trials for SLE
• Litifilimab — targets BDCA2 on plasmacytoid dendritic cells, addressing the interferon pathway from a different angle
• Low-dose IL-2 — aims to boost regulatory T cells (the immune system's natural brakes) rather than suppressing the immune system broadly

What This Means for Patients

The treatment landscape for lupus in 2026 is the most promising it has ever been. But navigating it requires ongoing conversations with your rheumatologist about:

• Whether your current regimen is optimal — if you are not well-controlled on standard therapy, biologic options exist
• Clinical trial eligibility — if you have refractory disease, ask about trials in your area
• Treatment goals — the field is moving toward low disease activity and steroid-free remission as realistic targets, not just "managing symptoms"

Staying Informed With Lycana

Tracking your disease activity over time helps you and your doctor make better treatment decisions. Lycana's symptom tracking, lab monitoring, and flare prediction tools give you objective data to bring to these conversations — so when you discuss whether a new treatment might be right for you, you have the evidence to back it up.

---

This article is for informational purposes only and does not constitute medical advice. Treatment decisions should always be made with your rheumatologist based on your individual disease profile.